PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Aging Cell. Author manuscript; available in PMC 2012 June 15.
Published in final edited form as:
PMCID: PMC3376089
NIHMSID: NIHMS241800

Perspectives on herpes-APP interactions

We recently reported a physical association between the herpes simplex virus type 1 (HSV) that causes the common cold sore and the amyloid precursor protein (APP) whose proteolytic fra­gment, Ab, is the major component of senile plaques in Alzhe­imer’s disease (Satpute-Krishnan, DeGiorgis and Bearer 2003). This physical association raises many new questions concerning a role for HSV infection in central nervous system function, including whether infection affects the risk of Alzheimer’s dis­ease or promotes other types of dementias.

Herpes simplex virus type 1 (HSV) infects the epithelial cells of the mucous membranes of the face where it secondarily infects sensory nerve terminals. Once within the neuron, HSV travels back to the neuronal cell body located in the trigeminal ganglion, which lies at the base of the skull adjacent to the brain stem. HSV remains in the ganglion in a latent form, until re­activation when newly synthesized virus is transported back to the mucous membrane. Until our study (Satpute-Krishnan et al., 2003), the molecular mechanisms of this transport were unknown. In fact, the mechanism by which any intracellular par­ticle, be it endogenous organelle or exogenous microbe, obtains motors for transport is a current major area of investigation in cell biology, as the large number of recent reviews and reports on this topic demonstrates.

We began our investigation with the goal of identifying the general mechanism by which a particle obtains a motor, using HSV as a tool to uncover universal paradigms governing this process. The identification of amyloid precursor protein (APP) as the putative motor receptor for HSV, and the implications of this for Alzheimer’s disease (AD), was a surprise – an unexpected result, a ‘discovery’. Our experiments began by demonstrating that HSV undergoes fast axonal transport when injected into the giant axon of the squid (Satpute-Krishnan et al., 2003). The squid axon allowed us to develop a novel functional assay that tests any exogenous particle, in this case HSV, for its ability to obtain motors and be transported. We had previously used this assay to demonstrate that removal of the viral envelope mimicked infection and produced HSV capable of being transported in the retrograde direction towards the neuronal cell body upon injection into the squid axon (Bearer et al., 2000). These initial results revealed the highly conserved nature of the transport process, which supported our idea that experiments using a human virus in a squid axon would produce universally applicable paradigms.

To discover the molecular basis of this activity, we undertook a ‘candidate gene’ approach. APP was selected based on work from the Goldstein laboratory that was published just after our first experiments had successfully reconstituted HSV motility in the giant axon. It had long been known that APP, a transmem­brane glycoprotein, was transported to the cell surface and, in neurons, to synaptic terminals (Koo et al., 1990). Goldstein’s work showed that APP (1) bound the microtubule motor, kinesin, through its light chains (Kamal et al., 2000), (2) was associated with transport vesicles (Kamal et al., 2000, 2001) and (3) produced similar phenotypes to kinesin when disrupted in Drosophila (Gunawardena & Goldstein, 2001).

Our biochemical and morphological analyses of HSV revealed that motile virus was physically associated with large amounts of cellular APP. Thus we now believe that APP plays a role in the anterograde transport of HSV from its site of synthesis in the cell body to distant neuronal termini. Whether this role is direct or indirect remains to be tested in a functional assay, and we are in process of doing this (P. Satpute-Krishnan et al., in preparation).

That HSV associates to such a degree with APP has raised numerous and disturbing questions. APP is a known risk factor for AD as the parent protein of the toxic Aβ fragments thought by some to be the primary factor causing synaptic dysfunction and neurodegeneration. Once we discovered this association, we were excited to find reports on epidemiological correlates between the presence of HSV DNA in the central nervous system (CNS) and AD, particularly those by Itzhaki and co-workers (Itzhaki et al., 1997, 2001; Dobson & Itzhaki, 1999; Grant et al., 2002). However, there is a wide gap between these epidemiological correlations and the molecular interactions between the virus and APP that we discovered. The accompanying correspondence by Itzhaki et al. raises a number of intriguing questions that should prompt many new and significant studies.

One key question is whether HSV enters the CNS via transport within neurons from the trigeminal pathway. This is certainly possible. The trigeminal ganglion contains bipolar neurons, each of which extends processes both to the periphery and into the CNS to synapse in the midbrain (the principal sensory trigeminal nucleus and spinal trigeminal nucleus) or in the amygdala (Fig. 1) (Jasmin et al., 1997).

Fig. 1
Hypothetical pathway of HSV transport to the brain via bipolar neurons in the trigeminal ganglion. HSV type 1 enters the sensory nerve terminals in the mucous membranes of the face by fusing viral envelope with the neuronal surface membrane. The viral ...

Other mechanisms of viral entry have also been proposed, including spread through the meninges or haemaotological dissemination during the viraemia of the initial infection (Burgos et al., 2002). For the latter, a role for one of the lipoproteins that transports lipid in serum, ApoE, has been proposed. The ApoE4 allele is known to be associated with AD (Holtzman et al., 2000; Mahley & Rail, 2000). Itzhaki and co­workers have shown an increased risk in patients with both the ApoE4 allele and HSV infection in a small cohort of cases (Itzhaki et al., 1997; Dobson & Itzhaki, 1999).

These correlations raise another key question: what role does ApoE play in HSV susceptibility and consequent pathogenicity? In addition to its potential role in haematogenous dissemination of HSV, ApoE might be involved in the transmission of virus within the nervous system by promoting viral passage across the synapse. ApoE is a component of senile plaques and localizes at synapses in the CNS. It is endocytosed by LPR1, a lipoprotein receptor that also binds the APP-secreted fragment (Kounnas et al., 1995; Pietrzik et al., 2002). One unexplored possibility is that this endocytotic event might mediate HSV transmission between neurons, possibly at the synapse. There are no current data on whether HSV crosses synapses, and if so what receptors receive the virus and allow entry, nor do we know if the virus has any direct effect on synaptic transmission.

Finally, most of what we know about HSV comes from its behaviour in the peripheral nervous system. We currently assume that HSV behaviour in the CNS is similar, but this remains unproven. Variables that will be important to consider when attempting to link HSV infection with age of onset, rate of progression, and type and severity of cognitive dysfunction include amount and location of HSV in the CNS, viral strain, age of infection and numbers of latency-eruption cycles. A recent report from Finland did not find correlation between HSV infection and AD (Hemling et al., 2003), suggesting that other variables in the affected population may also contribute to Alzheimer’s risk. The correspondence by Itzhaki et al. raises the intriguing idea that HSV synthesis may continue at low levels even during latency periods. In fact, several studies show that HSV is shed in saliva in a small number of infected people (1–5%) without causing symptoms, i.e. an ulcer (Hatherley et al., 1980; Okinaga, 2000). If a constant low level of viral production occurs asymptomatically in the brain, chronic neuronal damage could ensue.

One question is the source of the APP in our study. We used HSV synthesized in infected Vero cells, a monkey kidney epithelial cell line. Vero cells express all three of the APP homologues, APP, APLP1 and APLP2 (Lo et al., 1995), each of which contains the first seven amino acids of the 15 amino acid epitope from the C-terminus of APP recognized by our antibody, GTENPTYKFFEQMQN. Thus, our study may not distinguish between these homologues and it is possible that in Vero cells HSV associates with all three isoforms. APLP1 and APLP2 are also expressed in neurons and localize with APP in senile plaques (Crain et al., 1996; Galvan et al., 2002). Although cleavage of APLP1 and APLP2 does not produce the toxic Aβ fragment, the proteolysis of these two isoforms is neurotoxic (Galvan et al., 2002). Thus HSV would be predicted to damage neurons via APP regardless of which isoform it binds. Because we do not yet know the specific chemical basis of the interaction between APP and HSV, we cannot determine how specific this interaction is for one or the other isoform.

Could the virus itself encode an APP-like protein that is recognized by our anti-APP peptide antibody? Indeed, the viral envelope glycoprotein, gB, has some homology to the N-terminus of AP: 33% identity, 64% similarity in a 42-amino-acid sequence from aa 1 to 42 in APP (Cribbs et al., 2000). However, a Blast search of the NCBI database for viruses [ORGN] with the C-terminal peptide sequence of APP yielded 106 hits but no matches to HSV proteins even though all are expected in the database (search performed January 2004 by M. Conley and E. L. Bearer, unpublished data). Furthermore, our data show that the size of the C-APP antigen detected in Western blots is ~120 kDa, consistent with the size of cellular APP and not with the smaller viral gB (55 kDa) (Satpute-Krishnan et al., 2003). These results demonstrate that the APP antigen associated with HSV harvested from Vero cells derives from the host cell.

HSV is among the largest human viruses known, with a genome of ~ 152 kb encoding 87 proteins in 89 reading frames. These proteins interact and interfere with host cell machinery in numerous ways – transcriptional regulation, phosphorylation and replication have been the most studied. Recent data sug­gest interactions of the viral protein, VP22, with cellular proteins involved in RNA trafficking and processing (Sciortino et al., 2002). Our data indicate interactions of HSV with host cell membrane trafficking and transport factors including motors and their receptors (Satpute-Krishnan et al., 2003). These many activities of viral proteins combine to produce a cytotoxic effect on epithelial cells. In neurons, HSV infection seems to be less immediately toxic, possibly in part because of the HSV LAT gene product associated with viral latency and, selectively expressed in neurons, which inhibits apoptosis (Bloom, 2004). Should HSV cause defects in transport within neurons, which our data suggest, this alone could account for synaptic dysfunction (Bayer et al., 2001; Higuchi et al., 2002; Koo, 2002; Morfini et al., 2002). The additional toxic effect of a viral infection together with repeated rounds of viral synthesis and transport could cause multiple functional defects in an infected neuron that cumulatively result in synaptic failure and consequent cognitive impairment. To determine how these many variables might induce or exacerbate AD is the next challenge.

Acknowledgments

This work is supported by NIH-NIGMS 47368

References

  • Bayer TA, Wirths O, Majtenyi K, Hartmann T, Multhaup G, Beyreuther K, Czech C. Key factors in Alzheimer’s disease: beta-amyloid pre­cursor protein processing, metabolism and intraneuronal transport. Brain Pathol. 2001;11:1–11. [PubMed]
  • Bearer EL, Breakefield XO, Schuback D, Reese TS, LaVail JH. Retrograde axonal transport of herpes simplex virus: evidence for a single mechanism and a role for tegument. Proc Natl Acad Sci USA. 2000;97:8146–8150. [PubMed]
  • Bloom DC. Hsv Lat and neuronal survival. Int Rev Immunol. 2004;23:187–198. [PubMed]
  • Burgos JS, Ramirez C, Sastre I, Bullido MJ, Valdivieso F, Selkoe DJ. Involvement of apolipoprotein E in the hematogenous route of herpes simplex virus type 1 to the central nervous system. J Virol. 2002;76:12394–12398. [PMC free article] [PubMed]
  • Crain BJ, Hu W, Sze CI, Slunt HH, Koo EH, Price DL, Thinakaran G, Sisodia SS. Expression and distribution of amyloid precursor protein-like protein-2 in Alzheimer’s disease and in normal brain. Am J Pathol. 1996;149:1087–1095. [PubMed]
  • Cribbs DH, Azizeh BY, Cotman CW, LaFerla FM. Fibril formation and neurotoxicity by a herpes simplex virus glycoprotein B fragment with homology to the Alzheimer’s A beta peptide. Biochemistry. 2000;39:5988–5994. [PubMed]
  • Dobson CB, Itzhaki RF. Herpes simplex virus type 1 and Alzheimer’s disease. Neurobiol Aging. 1999;20:457–465. [PubMed]
  • Galvan V, Chen S, Lu D, Logvinova A, Goldsmith P, Koo EH, Bredesen DE. Caspase cleavage of members of the amyloid precursor family of proteins. J Neurochem. 2002;82:283–294. [PubMed]
  • Grant WB, Campbell A, Itzhaki RF, Savory J. The significance of environmental factors in the etiology of Alzheimer’s disease. J Alzheimers Dis. 2002;4:179–189. [PubMed]
  • Gunawardena S, Goldstein LS. Disruption of axonal transport and neuronal viability by amyloid precursor protein mutations in Drosophila. Neuron. 2001;32:389–401. [PubMed]
  • Hatherley LI, Hayes K, Jack I. Herpes virus in an obstetric hospital. II Asymptomatic virus excretion in staff members. Med J Aust. 1980;2:273–275. [PubMed]
  • Hemling N, Roytta M, Rinne J, Pollanen P, Broberg E, Tapio V, Vahlberg T, Hukkanen V. Herpesviruses in brains in Alzheimer’s and Parkinson’s diseases. Ann Neurol. 2003;54:267–271. [PubMed]
  • Higuchi M, Lee VM, Trojanowski JQ. Tau and axonopathy in neurodegenerative disorders. Neuromolecular Med. 2002;2:131–150. [PubMed]
  • Holtzman DM, Bales KR, Tenkova T, Fagan AM, Parsadanian M, Sartorius LJ, Mackey B, Olney J, McKeel D, Wozniak D, Paul SM. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer’s disease. Proc Natl Acad Sci USA. 2000;97:2892–2897. [PubMed]
  • Itzhaki RF, Dobson CB, Lin WR, Wozniak MA. Association of HSV1 and apolipoprotein E-varepsilon4 in Alzheimer’s disease. J Neurovirol. 2001;7:570–571. [PubMed]
  • Itzhaki RF, Lin WR, Shang D, Wilcock GK, Faragher B, Jamieson GA. Herpes simplex virus type 1 in brain and risk of Alzheimer’s disease. Lancet. 1997;349:241–244. [PubMed]
  • Jasmin L, Burkey AR, Card JP, Basbaum AI. Transneuronal labeling of a nociceptive pathway, the spino-(trigemino-) parabrachio-amygdaloid, in the rat. J Neurosci. 1997;17:3751–3765. [PubMed]
  • Kamal A, Almenar-Queralt A, LeBlanc JF, Roberts EA, Goldstein LS. Kinesin-mediated axonal transport of a membrane compartment containing beta-secretase and presenilin-1 requires APP. Nature. 2001;414:643–648. [PubMed]
  • Kamal A, Stokin GB, Yang Z, Xia CH, Goldstein LS. Axonal transport of amyloid precursor protein is mediated by direct binding to the kinesin light chain subunit of kinesin-I. Neuron. 2000;28:449–459. [PubMed]
  • Koo EH. The beta-amyloid precursor protein (APP) and Alzheimer’s disease: does the tail wag the dog? Traffic. 2002;3:763–770. [PubMed]
  • Koo EH, Sisodia SS, Archer DR, Martin LJ, Weidemann A, Beyreuther K, Fischer P, Masters CL, Price DL. Precursor of amyloid protein in Alzheimer disease undergoes fast anterograde axonal transport. Proc Natl Acad Sci USA. 1990;87:1561–1565. [PubMed]
  • Kounnas MZ, Moir RD, Rebeck GW, Bush AI, Argraves WS, Tanzi RE, Hyman BT, Strickland DK. LDL receptor-related protein, a multifunctional ApoE receptor, binds secreted beta-amyloid precursor protein and mediates its degradation. Cell. 1995;82:331–340. [PubMed]
  • Lo AC, Thinakaran G, Slunt HH, Sisodia SS. Metabolism of the amyloid precursor-like protein 2 in MDCK cells. Polarized trafficking occurs independent of the chondroitin sulfate glycosaminoglycan chain. J Biol Chem. 1995;270:12641–12645. [PubMed]
  • Mahley RW, Rall SC., Jr Apolipoprotein E: far more than a lipid transport protein. Annu Rev Genomics Hum Genet. 2000;1:507–537. [PubMed]
  • Morfini G, Pigino G, Beffert U, Busciglio J, Brady ST. Fast axonal transport misregulation and Alzheimer’s disease. Neuromolecular Med. 2002;2:89–99. [PubMed]
  • Okinaga S. Shedding of herpes simplex virus type 1 into tears and saliva in healthy Japanese adults. Kurume Med J. 2000;47:273–277. [PubMed]
  • Pietrzik CU, Busse T, Merriam DE, Weggen S, Koo EH. The cytoplasmic domain of the LDL receptor-related protein regulates multiple steps in APP processing. EMBO J. 2002;21:5691–5700. [PubMed]
  • Satpute-Krishnan P, DeGiorgis JA, Bearer EL. Fast anterograde transport of herpes simplex virus: role for the amyloid precursor protein of Alzheimer’s disease. Aging Cell. 2003;2:305–318. [PubMed]
  • Sciortino MT, Taddeo B, Poon AP, Mastino A, Roizman B. Of the three tegument proteins that package mRNA in herpes simplex virions, one (VP22) transports the mRNA to uninfected cells for expression prior to viral infection. Proc Natl Acad Sci USA. 2002;99:8318–8323. [PubMed]